{"id":"07c362526d84","type":"article","url":"https://hartvaat.nl/2016/08/01/magnesiumsuppletie-en-bloeddruk-meta-analyse-van-dubbelblinde-placebogecontrolee/","title":"Magnesiumsuppletie en bloeddruk: meta-analyse van dubbelblinde placebogecontroleerde trials","title_en":"Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials.","category":"hypertensie","category_label":"Hypertensie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["bloeddrukbehandeling","lipidenverlaging"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.116.07664","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.116.07664","authors":["Xi Zhang","Yufeng Li","Liana C Del Gobbo","Andrea Rosanoff","Jiawei Wang","Wen Zhang","Yiqing Song"],"significance":7,"published":"2016-08-01","source_date":"2016-08-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/ace-remmers-hypertensie/","https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/"],"congress":"","summary_en":"This meta-analysis of randomized double-blind placebo-controlled trials demonstrated that magnesium supplementation significantly lowers blood pressure, with dose-dependent effects. The findings support magnesium as an adjunctive nutritional strategy for blood pressure management.","created":"2026-07-03T10:26:15Z","updated":"2026-07-03T18:38:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Meta-analyse die aantoont dat magnesiumsuppletie de bloeddruk significant verlaagt. Kwantificeert het bloeddrukverlagend effect en ondersteunt magnesium als aanvulling op antihypertensieve behandeling.","abstract_original":"The antihypertensive effect of magnesium (Mg) supplementation remains controversial. We aimed to quantify the effect of oral Mg supplementation on blood pressure (BP) by synthesizing available evidence from randomized, double-blind, placebo-controlled trials. We searched trials of Mg supplementation on normotensive and hypertensive adults published up to February 1, 2016 from MEDLINE and EMBASE databases; 34 trials involving 2028 participants were eligible for this meta-analysis. Weighted mean differences of changes in BP and serum Mg were calculated by random-effects meta-analysis. Mg supplementation at a median dose of 368 mg/d for a median duration of 3 months significantly reduced systolic BP by 2.00 mm Hg (95% confidence interval, 0.43-3.58) and diastolic BP by 1.78 mm Hg (95% confidence interval, 0.73-2.82); these reductions were accompanied by 0.05 mmol/L (95% confidence interval, 0.03, 0.07) elevation of serum Mg compared with placebo. Using a restricted cubic spline curve, we found that Mg supplementation with a dose of 300 mg/d or duration of 1 month is sufficient to elevate serum Mg and reduce BP; and serum Mg was negatively associated with diastolic BP but not systolic BP (all P<0.05). In the stratified analyses, a greater reduction in BP tended to be found in trials with high quality or low dropout rate (all P values for interaction <0.05). However, residual heterogeneity may still exist after considering these possible factors. Our findings indicate a causal effect of Mg supplementation on lowering BPs in adults. Further well-designed trials are warranted to validate the BP-lowering efficacy of optimal Mg treatment."}